Literature DB >> 21842255

Acute myocardial infarction in a teenager due to Adderall XR.

Angela L Sylvester1, Brojendra Agarwala.   

Abstract

Adderall XR is commonly prescribed for children and adolescents with attention deficit/hyperactivity disorder. We present a case of a 15-year-old male who suffered a myocardial infarction after starting Adderall XR. Patient was otherwise in good health with no previous cardiac abnormalities. Cardiac catheterization was normal, and etiology was presumed to be secondary to acute vasospasm. The patient improved with cessation of medication. Physicians need to carefully screen patients for cardiac abnormalities prior to starting amphetamine-based medications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21842255     DOI: 10.1007/s00246-011-0083-9

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  4 in total

1.  Myocardial infarction in an adolescent taking Adderall.

Authors:  Pritesh J Gandhi; Gladys U Ezeala; Tuonglan T Luyen; Tran C Tu; Maichi T Tran
Journal:  Am J Health Syst Pharm       Date:  2005-07-15       Impact factor: 2.637

2.  Outcomes after accidental pediatric ingestions of (dextro)amphetamine and methylphenidate.

Authors:  Frank LoVecchio; John Ozimek; Belinda Sawyers; Dan Thole
Journal:  Am J Emerg Med       Date:  2009-10       Impact factor: 2.469

3.  Acute myocardial infarction resulting from amphetamine abuse: a spasm-thrombus interplay?

Authors:  T T Bashour
Journal:  Am Heart J       Date:  1994-12       Impact factor: 4.749

4.  Myocardial infarction associated with adderall XR and alcohol use in a young man.

Authors:  Xiangyang Jiao; Sonia Velez; Jennifer Ringstad; Valerie Eyma; Daniel Miller; Melvyn Bleiberg
Journal:  J Am Board Fam Med       Date:  2009 Mar-Apr       Impact factor: 2.657

  4 in total
  3 in total

1.  Not acute myocardial infarction in a teenager due to Adderall XR.

Authors:  Eric Rosenthal
Journal:  Pediatr Cardiol       Date:  2012-02-22       Impact factor: 1.655

Review 2.  Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Authors:  Jose Martinez-Raga; Carlos Knecht; Nestor Szerman; María I Martinez
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

3.  Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects.

Authors:  Shaheen E Lakhan; Annette Kirchgessner
Journal:  Brain Behav       Date:  2012-07-23       Impact factor: 2.708

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.